SCHEMBL9883183

SCHEMBL9883183

CCc1ccc2c(O)ncc(Cl)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.40
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
L3MBTL1 Q9Y468 4/20 0.33
KDM4E B2RXH2 2/20 0.33
KIF11 P52732 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
RAD52 P43351 1/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
NPC1 O15118 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9883135 0.81 TRPA1 (0.41) TRPA1NOS3NOS1NOS2L3MBTL1
SCHEMBL9883213 0.80 TRPA1 (0.40) TRPA1NOS3NOS1NOS2L3MBTL1
SCHEMBL13074891 0.77 PLG (0.43) TRPA1KDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL30011684 0.77 ALDH1A1 (0.40) SMN1; SMN2MEN1ALDH1A1KMT2ATDP1
SCHEMBL15005588 0.77 ALDH1A1 (0.40) SMN1; SMN2MEN1ALDH1A1KMT2ATDP1
SCHEMBL9880942 0.73 ALDH1A1 (0.40) KDM4EKIF11SMN1; SMN2MEN1ALDH1A1
SCHEMBL19256235 0.73 CNR2 (0.37)
SCHEMBL12804693 0.70 ALDH1A1 (0.52) KDM4ESMN1; SMN2MEN1ALDH1A1HTT
SCHEMBL9883268 0.69 CYP1A2 (0.41) TRPA1KDM4EKIF11SMN1; SMN2MEN1
SCHEMBL22280318 0.69 IRAK4 (0.46) TRPA1NOS3NOS1NOS2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394826-B2 Dual mechanism inhibitors for the treatment of disease AERIE PHARMACEUTICALS, INC. (US) 2013-03-12 US disclosed
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME AERIE PHARMACEUTICALS, INC. 2012-05-31 US disclosed
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE ALCON INC. (CH) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME SLC6A2, ROCK2, SLC6A4 TRPA1 4080/4885NOS3 323/4885NOS1 235/4885
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE RHOA, SLC6A2, ROCK2 TRPA1 3206/4885NOS3 123/4885NOS1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.